|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
In contrast, in basal-like tumours, c-MYC showed positive association with Cyclin E (P=0.003) and p16 (P=0.042) expression only. c-MYC was an independent predictor of a shorter distant metastases-free survival in luminal A LN+ tumours treated with endocrine therapy (ET; P=0.013).
|
26954716 |
2016 |
|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Nevertheless, both c-MYC and ß-catenin expression in primary cancer were significantly correlated with improved survival in univariate (P = 0.001) and multivariate (P = 0.002) analyses. c-MYC and ß-catenin expression of lymph node or distant metastatic tumor was not significantly correlated with patients' prognosis (P > 0.05).
|
27619912 |
2016 |
|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
The interaction between YWHAE and MYC and the activation of the pathways related to this interaction play a role in the metastasis process.
|
27863420 |
2016 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
By bioinformatic analysis, we confirmed the important role of miR-340 as a pivotal regulator of breast cancer metastasis in targeting previously validated (ROCK1) and potentially novel genes, i.e., (CTNNB1 and c-MYC).
|
26758430 |
2016 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
MYC-nick promotes the migration of colon cancer cells assayed in 3D cultures or grown as xenografts in a zebrafish metastasis model.
|
27566402 |
2016 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
This potential path highlights the crucial role of BMP2, hsa-miR-24, AP2 and MYC as the up-stream regulators of the path and hsa-miR-215 and TYMS as potential indicator of chemotherapeutic benefit in STS metastasis.
|
25984907 |
2015 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Our data identify IL6 detection as a potential causal biomarker for MYC-driven metastasis after loss of PTEN and p53.
|
25829425 |
2015 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
As the preliminary results showed a higher proportion of copy number alteration (CNA) at 8q24 (MYC loci) and the available evidence supporting the role of MYC in the processes cancer metastases is conflicting, MYC status was determined in tissue microarray sections in a larger series of patients (n = 49) with known CTC status using FISH.
|
25286758 |
2015 |
|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
The c-MYC gene is activated in approximately half of all tumors, and its product, the c-MYC transcription factor, regulates numerous processes e.g. cell cycle progression, metabolism, epithelial-mesenchymal transition (EMT), metastasis, stemness, and angiogenesis, thereby facilitating tumor initiation and progression. c-MYC target-genes, which mediate these functions of c-MYC, represent a complex network of protein- and non-coding RNAs, including numerous miRNAs.
|
24727092 |
2015 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
C-MYC immunostaining was significantly associated with clinical T stage (P < 0.001), distant metastasis at the time of diagnosis (P < 0.001) and TMPRSS2-ERG status (P = 0.001) but not with ERG immunostaining (P = 0.818).
|
25973080 |
2015 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
In spite of the above limitations, a few biomarkers including the proliferation marker Ki-67 and genetic markers such as c-MYC and PTEN have consistently shown their independent prognostic impact both for biochemical recurrence and for clinical outcome parameters such as metastatic disease or prostate-specific mortality.
|
24487790 |
2014 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
This review summarizes the latest progress on the investigation of lncRNAs and MYC, particularly focusing on the interplay between lncRNAs and MYC in cancer to reveal the significance of lncRNA-MYC network in regulating initiation, development, and metastasis of tumors.
|
25139102 |
2014 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Amplification at the MYC locus was observed in 29% of cases and was closely associated with both disease progression (from 15% in pT2 tumors to 53% in metastasis; P = .001), and Gleason score (from <3% in Gleason 6 tumors to 66% in Gleason 8 and more tumors; P < .0001).
|
23574779 |
2013 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Here, we focus on GATA4 as a MYC target in the development of metastasis with origin in lung adenocarcinoma, the most common type of NSCLC.
|
23239811 |
2013 |
|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
The overexpression of MYC was more frequently found in PCa tissues with positive metastasis (P = 0.02) and PSA failure (P = 0.02).
|
23377984 |
2013 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
The gain of MYC copies was associated with late-onset, intestinal-type, advanced tumor stage, and the presence of distant metastasis (p<0.05).
|
23717612 |
2013 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Isochromosome 17q, MYC amplification and large cell/anaplastic phenotype in a case of medullomyoblastoma with extracranial metastases.
|
22147345 |
2012 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Previous reports using array comparative genomic hybridization (aCGH) in radical prostatectomy cohorts suggested a combination of allelic loss of the PTEN gene on 10q and allelic gain of the c-MYC gene on 8q were associated with metastatic disease.
|
22281794 |
2012 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
MYC gains progressively increased during penile squamous cell carcinoma progression from in situ samples to metastases.
|
22999547 |
2012 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
We investigated here two 8q24 breast and colon cancer risk alleles in the close vicinity of the MYC gene for their role in the occurrence of distant metastases.
|
22666420 |
2012 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
These data uncover an unexpected function of MYC, provide an explanation for the hitherto puzzling literature on the relationship between MYC and metastasis, and reveal a variable that could influence the development of therapies that target MYC.
|
22581054 |
2012 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
CTD_human |
It is widely recognized that activation of MMP2 and MYC is tightly associated with tumor metastasis and tumor progression.
|
22321834 |
2012 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Specifically, whether the MYC amplification status may change in metastases in comparison to the corresponding primary breast tumor, and potential variability among different metastases within the same patient have also not been assessed.
|
22056952 |
2012 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
MYC and metastasis.
|
21406394 |
2011 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
High mRNA expression levels of HINT1, IFITM2, LGALS3BP, STOML2 and c-MYC were associated with reduced risk to death and lower risk to develop metastasis.
|
19544526 |
2010 |